484 related articles for article (PubMed ID: 17549314)
21. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.
Temperilli F; Rina A; Massimi I; Montemari AL; Guarino ML; Zicari A; Pulcinelli FM
Platelets; 2015; 26(8):783-7. PubMed ID: 25734355
[TBL] [Abstract][Full Text] [Related]
22. Aspirin resistance after coronary artery bypass grafting.
Zimmermann N; Kienzle P; Weber AA; Winter J; Gams E; Schrör K; Hohlfeld T
J Thorac Cardiovasc Surg; 2001 May; 121(5):982-4. PubMed ID: 11326244
[No Abstract] [Full Text] [Related]
23. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population.
Faraday N; Becker DM; Yanek LR; Herrera-Galeano JE; Segal JB; Moy TF; Bray PF; Becker LC
Am J Cardiol; 2006 Sep; 98(6):774-9. PubMed ID: 16950183
[TBL] [Abstract][Full Text] [Related]
24. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients.
Crescente M; Di Castelnuovo A; Iacoviello L; de Gaetano G; Cerletti C
Thromb Haemost; 2008 Jun; 99(6):1129-31. PubMed ID: 18521524
[No Abstract] [Full Text] [Related]
25. Differences in the in vitro antiplatelet effect of dexibuprofen, ibuprofen, and flurbiprofen in human blood.
De la Cruz JP; Reyes JJ; Ruiz-Moreno MI; Lopez-Villodres JA; Jebrouni N; Gonzalez-Correa JA
Anesth Analg; 2010 Dec; 111(6):1341-6. PubMed ID: 21048099
[TBL] [Abstract][Full Text] [Related]
26. Aspirin resistance: what, why and when?
Shantsila E; Watson T; Lip GY
Thromb Res; 2007; 119(5):551-4. PubMed ID: 17010411
[No Abstract] [Full Text] [Related]
27. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane.
Carroll RC; Craft RM; Snider CC; Aligeti VR; Wortham DC
Anesth Analg; 2013 Feb; 116(2):282-6. PubMed ID: 23302970
[TBL] [Abstract][Full Text] [Related]
28. Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population.
Mardikar H; Deo D; Deshpande N; Mardikar M; Ghosh A; Munot K; Steinhubl S; Mukherjee D
J Assoc Physicians India; 2008 May; 56():321-4. PubMed ID: 18700638
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of aspirin resistance in patients with type 2 diabetes.
Fateh-Moghadam S; Plöckinger U; Cabeza N; Htun P; Reuter T; Ersel S; Gawaz M; Dietz R; Bocksch W
Acta Diabetol; 2005 Jun; 42(2):99-103. PubMed ID: 15944844
[TBL] [Abstract][Full Text] [Related]
30. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
[TBL] [Abstract][Full Text] [Related]
31. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man--effect of low-dose aspirin.
Kyrle PA; Westwick J; Scully MF; Kakkar VV; Lewis GP
Thromb Haemost; 1987 Feb; 57(1):62-6. PubMed ID: 2954260
[TBL] [Abstract][Full Text] [Related]
32. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
Neubauer H; Lask S; Engelhardt A; Mügge A
Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
[TBL] [Abstract][Full Text] [Related]
33. The aspirin resistance controversy: clinical entity or platelet heterogeneity?
Freedman JE
Circulation; 2006 Jun; 113(25):2865-7. PubMed ID: 16801473
[No Abstract] [Full Text] [Related]
34. Aspirin resistance and diabetic angiopathy: back to the future.
Di Minno G; Violi F
Thromb Res; 2004; 113(2):97-9. PubMed ID: 15115664
[No Abstract] [Full Text] [Related]
35. A critical appraisal of the phenomenon of aspirin resistance.
Svenstrup Poulsen T; Kristensen SR; Atar D; Mickley H
Cardiology; 2005; 104(2):83-91. PubMed ID: 16020925
[TBL] [Abstract][Full Text] [Related]
36. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
[TBL] [Abstract][Full Text] [Related]
37. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.
DiChiara J; Bliden KP; Tantry US; Hamed MS; Antonino MJ; Suarez TA; Bailon O; Singla A; Gurbel PA
Diabetes; 2007 Dec; 56(12):3014-9. PubMed ID: 17848625
[TBL] [Abstract][Full Text] [Related]
38. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
[TBL] [Abstract][Full Text] [Related]
39. [A current problem in atherothrombotic diseases--aspirin resistance: definition, mechanisms, determination with laboratory tests and clinical implications].
Pamukçu B; Oflaz H; Nişanci Y
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():20-6. PubMed ID: 18160363
[TBL] [Abstract][Full Text] [Related]
40. Aspirin resistance.
Tran HA; Anand SS; Hankey GJ; Eikelboom JW
Thromb Res; 2007; 120(3):337-46. PubMed ID: 17241655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
